AMTH to Strengthen Position in Urology Through M&A

Advanced MedTech Holdings (AMTH or the Group) announced the acquisition of a majority interest in […]

Established in 1996, Wikkon has the largest installed base of over 6,000 urology treatment devices in China and strong relationships with healthcare professionals. The acquisition will significantly strengthen AMTH’s direct presence in China.

Combining the German engineering strength of Dornier MedTech, AMTH’s wholly owned subsidiary, with the innovative capabilities of WIKKON, AMTH will be able to offer physicians access to an expanded product portfolio and build up a high potential platform for the development of a global value segment in urology.

With China’s focus on domestic sourcing for key medical devices and its sizeable domestic market, AMTH said it is well-positioned to serve the expanded needs of the world’s second-largest and fastest growing healthcare market with deeper localization of R&D and manufacturing capabilities. Wikkon’s products are in use across more than 40 countries in Asia Pacific and the rest of the world, giving AMTH a strong platform to better serve the needs of global emerging markets from Wikkon’s base in Shenzhen.

Abel Ang, Group Chief Executive of Advanced MedTech, said: We are now uniquely placed to aggressively grow in China’s sizeable market, which is best served by domestically produced devices. Advanced MedTech’s integrated urology platform is accelerated by Wikkon’s significant R&D, manufacturing, supply chain, and installed base of units. Our newly combined portfolio will allow us to serve urology customers seeking value-oriented solutions right through to premium-oriented customers globally.”

Original Article: (